Introduction: Type 2 diabetes (T2D) is a major health concern associated with several 24 comorbidities such as diabetic chronic kidney disease, neuropathy, and cardiovascular diseases.
25
Many of these complications may be preventable by an adequate lifestyle, including a favourable 26 dietary behaviour, additionally to pharmacological management. In general, dietary guidelines for 27 patients with diabetes recommend a hypocaloric diet to achieve a normal weight, but there is a 28 lack of detailed instructions on specific nutrients and foods to prevent diabetes-related outcomes.
29
Therefore, the aim of this systematic review and meta-analysis is to summarise the available 30 evidence on the association between dietary factors and health-related outcomes in patients with 31 T2D.
32

Methods and analysis:
A systematic literature search will be conducted in PubMed and Embase 33 to identify prospective observational studies investigating dietary factors in association with major 34 complications in patients with T2D. We will include studies investigating dietary patterns, food 35 groups, foods, macro-and micronutrients as well as secondary plant compounds. As diabetes-36 related outcomes, we will include macrovascular (cardio-and cerebrovascular diseases) and 37 microvascular outcomes (nephropathy, neuropathy and retinopathy), as well as cancer, quality of 38 life, depression, cognitive disorders and mortality.
39
We will conduct dose-response meta-analyses using random effects models. We will investigate 40 heterogeneity across studies and publication bias. To assess the risk of bias and quality of the 41 included studies, we will use the Cochrane risk of bias tool ROBINS-I and the quality of evidence 
53

This systematic review will provide a comprehensive overview of dietary patterns, foods and 54 nutrients in association with a range of diabetes-related outcomes: macro-(cardiovascular 55 diseases) and microvascular outcomes (nephropathy, neuropathy, and retinopathy), cancer,
56
health-related quality of life, depression, cognitive disorders and mortality.
57

We will conduct linear and non-linear dose-response meta-analyses to investigate the impact 58 of different dietary factors on the risk of health-related outcomes in patients with type 2 59 diabetes.
60

We will include observational studies only, instead of RCTs, however, intervention studies are 61 mostly based on biomarkers for diabetes complications and do not focus on hard endpoints. The present protocol was planned, conducted, and reported according to the Preferred reporting 114 items for systematic review and meta-analysis protocols (PRISMA-P). 15 The systematic review 115 and meta-analysis was registered in PROSPERO International Prospective Register of 116 Systematic Reviews (registration number: CRD42018110669). Amendments to this protocol will 117 be included into updated versions of the PROSPERO, if needed.
119
Eligibility criteria
120
We will include studies in the systematic review and meta-analysis if the following criteria are met:
121
(1) Participants: We will include patients with T2D aged 18 or older. Studies which solely focused 122 on children, adolescents, participants with prediabetes, type 1 diabetes or gestational 123 diabetes will be excluded, as well as animal and cell culture studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
167
-total CVD, including coronary heart diseases and stroke,
168
-coronary heart diseases, including myocardial infarction, acute coronary syndrome, and 169 ischemic heart disease,
170
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244
We will conduct meta-analyses using a random effects model when two or more studies on the 245 same exposure and outcome are available by applying the method provided by DerSimonian and
246
Laird. 23 If a study reported only separate risk estimates for men and women, we will pool the data 247 using a fixed effect model before entering the study in the overall meta-analysis. We will focus on 248 dose-response meta-analyses and high versus low meta-analyses will only be conducted if 249 information on dose-response associations are lacking. We will conduct linear dose-response 250 meta-analyses using the method as described by Greenland and Longnecker. 24 In addition, we 251 will explore the shape of the association by conducting nonlinear dose-response meta-analysis as 252 described by Orsini et al. 25 This method requires the following data for at least three exposure 253 categories: the quantified exposure value (e.g. grams per day), the effect estimate with the 254 corresponding 95 % CI, and the number of cases and person-years. If the number of cases in 255 single categories has not been reported in one study, but information on the total number of cases 256 and total person-years or the number of total patients plus follow-up period have been provided, 257 the number of cases will be equally distributed across the quantiles, and for specified categories 258 as described previously. 26 If a range of dietary intake will be presented, the midpoint value will be 259 assigned as exposure level for the respective category. To investigate heterogeneity, we will 260 calculate tau-squared to assess the between-study variance and I 2 statistic to investigate the 261 variability of the observed effects in the meta-analyses. 27 We will also calculate prediction intervals 262 to present how widely the single study effects vary across the studies. 28 We will conduct subgroup 263 analyses and meta-regression to investigate possible sources of heterogeneity across studies 264 such as sex, age, study length study origin, duration of diabetes, medical treatment, if sufficient 265 data are available. Moreover, potential publication bias will be investigated visually using funnel 266 plots and Egger's test, whereas a p-value <0.1 indicates potential publication bias. 
279
As diabetes management is important to prevent comorbidities and dietary guidelines for patients 280 with T2D are scarce, this systematic review will provide important impact regarding evidence-281 based recommendations on dietary behaviour for patients with prevalent diabetes.
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This systematic review and meta-analysis will be published in a peer-reviewed Journal and will be 287 presented at scientific conferences. Reporting checklist for protocol of a systematic review.
Based on the PRISMA-P guidelines.
Instructions to authors
Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.
Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.
Upload your completed checklist as an extra file when you submit to a journal.
In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as: 
40
We will conduct dose-response meta-analyses using random effects models. We will 41 investigate heterogeneity across studies and publication bias. To assess the risk of bias and 42 quality of the included studies, we will use the Cochrane risk of bias tool ROBINS-I and the 43 quality of evidence will be assessed using GRADE. 
114 Methods
115
The present protocol was planned, conducted, and reported according to the Preferred 116 reporting items for systematic review and meta-analysis protocols (PRISMA-P). 16 The 117 systematic review and meta-analysis was registered in PROSPERO International Prospective 
164
We will include objectively measured outcomes such as CVD, neuropathy, nephropathy, 165 retinopathy, cancer, and mortality assessed through record linkage, death certificates, 166 disease-specific registries, medical records or accepted clinical criteria in the original papers; 167 as well as subjectively measured outcomes such as health-related quality of life, depression 168 and cognitive disorders evaluated by validated or established instruments. In particular, we will 169 focus on the following groups of outcomes:
170  Macrovascular outcomes: -coronary heart diseases, including myocardial infarction, acute coronary syndrome, 173 and ischemic heart disease, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 1 . Afterwards, we will screen the reference lists of all eligible studies and 197 relevant reviews to identify additional studies meeting our inclusion criteria. The search results
198
will be managed using the citation software Reference Manager (Version 12).
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221
We will exclude studies from the meta-analyses if we were unable to obtain relevant data. All 222 contacts with authors will be documented.
224
Study quality and risk of bias
225
To evaluate the study quality of the prospective studies and potential risks of bias, we will use 226 the risk of bias in nonrandomized studies of interventions (ROBINS-I) tool. 21 This tool was 227 proposed by Cochrane and can also be applied to assess the risk of bias in observational 228 studies. The tool is divided into the following domains: 1) bias due to confounding, 2) bias in 229 selection of participants into the study, 3) bias in measurement of the exposure, 4) bias due to 
237
If relevant information in at least one domain are missing, the study will be classified as no 238 information. Following the assessment of risk of bias, the body of evidence for each exposure 239 and outcome association will be rated using the Grades of Recommendation, Assessment,
240
Development, and Evaluation (GRADE) approach. 22 This method takes into account the within-241 study risk of bias, inconsistency, indirectness and imprecision between the studies, publication 242 bias, large magnitude of effect and dose-response relationship. Two reviewer will 243 independently assess the risk of bias of all included studies and rate the certainty of evidence.
244
Any disagreements between the two investigators will be resolved by consensus or 245 consultation of a third researcher.
247
Data analysis and presentation
248 Data analyses will be performed using the statistical software Stata (Version 14, StataCorp,
249
College Station, TX, USA). We will conduct meta-analyses using a random effects model when 250 two or more studies on the same exposure and outcome are available by applying the method 251 provided by DerSimonian and Laird. 23 We will separately investigate studies on dietary intake, 252 dietary supplements, and biomarkers of dietary intake. If a study reported only separate risk 253 estimates for men and women, we will pool the data using a fixed effect model before entering 254 the study in the overall meta-analysis. We will focus on dose-response meta-analyses and 255 high versus low meta-analyses will only be conducted if information on dose-response 256 associations are lacking. We will conduct linear dose-response meta-analyses using the 257 method as described by Greenland and Longnecker. 24 In addition, we will explore the shape provided, the number of cases will be equally distributed across the quantiles, and for specified 265 categories as described previously. 26 If a range of dietary intake will be presented, the midpoint 266 value will be assigned as exposure level for the respective category. To investigate 267 heterogeneity, we will calculate tau-squared to assess the between-study variance and I 2 268 statistic to investigate the variability of the observed effects in the meta-analyses. 27 We will 269 also calculate prediction intervals to present how widely the single study effects vary across 270 the studies. 28 We will conduct subgroup analyses and meta-regression to investigate possible 271 sources of heterogeneity across studies such as sex, age, study length study origin, duration 272 of diabetes, medical treatment, if sufficient data are available. Moreover, potential publication 273 bias will be investigated visually using funnel plots and Egger's test, whereas a p-value <0.1 274 indicates potential publication bias.
275
The results of the systematic review and meta-analyses will be reported according to the Meta-276 analysis Of Observational Studies in Epidemiology (MOOSE). 29 The characteristics and results
277
of all studies will be presented in summary tables and forest plots where appropriate.
278 and outcome selection. In a previous project, partly conducted at our institution, patients' 282 interests, information needs and preferences concerning diabetes research was assessed.
283
The study was conducted in 26 adults with diabetes from North Rhine-Westphalia, Germany.
284
The patients were interviewed in moderated focus groups and transcripts were analysed in a 285 multidisciplinary team using qualitative content analysis. 30 Patients with diabetes expressed Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) 6
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